Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy
Version of Record online: 3 DEC 2013
© 2013 British Society for Immunology
Clinical & Experimental Immunology
Volume 175, Issue 1, pages 49–58, January 2014
How to Cite
Chan, A. C., Neeson, P., Leeansyah, E., Tainton, K., Quach, H., Prince, H. M., Harrison, S. J., Godfrey, D. I., Ritchie, D. and Berzins, S. P. (2014), Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clinical & Experimental Immunology, 175: 49–58. doi: 10.1111/cei.12196
- Issue online: 3 DEC 2013
- Version of Record online: 3 DEC 2013
- Accepted manuscript online: 29 AUG 2013 06:43AM EST
- Manuscript Accepted: 21 AUG 2013
- National Health and Medical Research Council (NHMRC). Grant Numbers: 454363, 251608, 454569
- Fiona Elsey Cancer Research Institute (FECRI)
- Victorian Cancer Agency
Fig. S1. Multiple myeloma clinical trial design. Previously untreated newly diagnosed patients were enrolled onto the Litvacc study (a), where following lenalidomide + dexamethasone (LEN + DEX) induction the patients received an autologous stem cell transplantation (ASCT) followed by myeloma lysate-pulsed dendritic cells (DCs) + LEN maintenance or len maintenance alone (in our study, 10 of 11 patients received myeloma lysate-pulsed DCs + LEN maintenance). Patients with refractory relapsed disease were enrolled into the RevLite study (b) to receive LEN + DEX induction, then repeated cycles of LEN + DEX until disease progression. A comparison between the two trials is provided in table (c) including disease state, drug dose and cycles of therapy.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.